title: Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
abstract: OBJECTIVE
  A significant benefit of imatinib adjuvant therapy for patients with high risk gastrointestinal stromal tumors (GIST) has been confirmed. However, the effect of imatinib adjuvant therapy for intermediate-risk GIST has not been well studied. In this article, we compare differences of recurrence-free survival (RFS) rates between patients with intermediate-risk GIST who accepted imatinib adjuvant therapy and those who did not.
  
  
  METHODS
  A retrospective study of intermediate-risk GIST was conducted in the First Affiliated Hospital of Zhengzhou University, China. The pathology reports of 112 patients who had been treated by surgery showed intermediate-risk GIST. The treatment and control groups were designed according to the administration of imatinib adjuvant therapy (≥1 year). Survival and recurrence data were collected and RFS of each group was calculated.
  
  
  RESULTS
  Eighty fivepatients with intermediate-risk GIST were followed up. Thirty of them (treatment group) accepted imatinib adjuvant therapy over 1 year. Through comparing the RFS of the two groups, we established that there was no statistically significant difference in RFS rates (P=0.940).
  
  
  CONCLUSIONS
  There is no significant benefit for patients with intermediate-risk GIST to accept imatinib adjuvant treatment.
authors.affiliation: Department of General Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Fu
authors.affiliation: Department of General Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
authors.forename: He
authors.initials: H
authors.lastname: Hao
authors.affiliation: Department of General Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
authors.forename: Luwei
authors.initials: L
authors.lastname: Guo
authors.affiliation: Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
authors.forename: Ge
authors.initials: G
authors.lastname: Yang
authors.affiliation: Department of General Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
authors.forename: Xiefu
authors.initials: X
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002681:China; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000556:secondary; D006801:Humans; D000068877:Imatinib Mesylate / Q000009:adverse effects / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D000068877:Imatinib Mesylate
keywords: GIST; RFS; imatinib; intermediate-risk; retrospective analysis